+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

RNA Based Therapeutic Market by Disease Type, Application and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 170 Pages
  • December 2021
  • Region: Global
  • Allied Market Research
  • ID: 5548449
The global RNA based therapeutics market generated $4,938.38 million in 2021, and is projected to reach $25,121.95 million by 2030, growing at a CAGR of 17.6% from 2021 to 2030.



RNA based therapeutics is a class of medications based on ribonucleic acid (RNA). RNA based therapeutics provides or modifies ribonucleic acid (RNA) to patients’ cells. Now it has the potential to treat a wide variety of diseases, including cardiovascular disease, hemophilia, and cancer. Based on messenger RNA (mRNA), the main types of RNA therapeutics include antisense RNA (asRNA), RNA interference (RNAi), the agents of RNA interference (RNAi), catalytically active RNA molecules (ribozymes), and RNAs that bind proteins and other molecular ligands (aptamers). In addition, messenger RNA (mRNA) can be used as protein replacement therapy to treat diseases caused by a lack of protein, or by defective proteins, such as cystic fibrosis. Moreover, Prominent players in the global RNA based therapeutics market have opted various strategies such as type launches, approvals, and investments in R&D for advancement in RNA based therapeutics to strengthen their position in the market and sustain the competitive environment

The global RNA based therapeutics market has garnered significant attention in the recent years due to its potential to treat variety of chronic diseases such as cancer, diabetes, Human immunodeficiency virus infection and acquired immune deficiency syndrome (AIDS), Tuberculosis and certain cardiovascular conditions and rise in government initiatives to promote healthy lifestyle. Furthermore, rise in health awareness significantly contributes toward the growth of the market. However, factors such as dearth of skilled professionals and end-user budget constraints in developing countries are expected to restrain the market growth. Conversely, surge in number of applications in molecular diagnostics, particularly in cancer and improving synthetic delivery carriers and chemical modifications to RNA is expected to offer profitable opportunities for the market players in the near future. Furthermore, increase in demand for genomic sequencing in laboratories, and research centers, also increasing molecular diagnostics are expected to provide lucrative opportunities for the growth of the market in near future.

RNA based therapeutics is segmented into by type, by application, and by end user. Based on type, the market is segmented into RNA interference (RNAi) technologies and RNA antisense technologies. Based on application, the market is segmented into genetic disorders and auto immune disorders. Based on end user, the market is segmented into research institutes, and hospitals & clinics. Region wise, it is classified into the North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global RNA based therapeutic market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the products and end users of RNA based therapeutic used across the globe.
  • Key market players and their strategies have been analysed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS


By Type

  • RNA Interference (RNAi)
  • RNA antisense

By Application

  • Genetic disorders
  • Auto immune disorders

By End User

  • Research Institutes
  • Hospitals & Clinics
  • By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Australia
  • Japan
  • China
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Alnylam Pharmaceuticals, Inc.
  • Silence Therapeutics plc
  • Arbutus Biopharma Corporation
  • Genzyme (Sanofi)
  • Ionis Pharmaceuticals
  • Sarepta Therapeutics
  • Benitec Biopharma Inc
  • Arrowhead Pharmaceuticals
  • Biogen, Inc
  • Gradalis, Inc.

Table of Contents

CHAPTER 1- INTRODUTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Key Players
1.5. Research methodology
1.5.1. Secondary research
1.5.2. Primary research
1.5.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Top player positioning, 2020
3.4. Porter’s five forces analysis
3.4.1. Bargaining power of suppliers
3.4.2. Bargaining power of buyers
3.4.3. Threat of new entrants
3.4.4. Threat of substitutes
3.4.5. Intensity of competitive rivalry
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Target Specificity and Selectivity of Treatment
3.5.1.2. Initiatives From Government for Large-Scale Sequencing Projects
3.5.2. Restraints
3.5.2.1. Hurdles In Drug Delivery
3.5.2.2. High Cost of Research and Threat of Failure
3.5.3. Opportunities
3.5.3.1. Early Commercialization of Pipeline Therapeutics Assists to Gain Competitive Advantage
3.5.3.2. Multifactorial Disease Targeting
3.5.4. Impact Analysis
3.1. COVID-19 impact analysis on the RNA based therapeutics market
CHAPTER 4: RNA BASED THERAPEUTICS MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast, by Type
4.2. RNA Interference (RNAi)
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. RNA Antisense
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
CHAPTER 5: RNA BASED THERAPEUTICS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast, by end user
5.2. Genetic Disorders
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Auto immune disorders
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
CHAPTER 6: RNA BASED THERAPEUTICS MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast, by end user
6.2. Research Institutes
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Hospitals & Clinics
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
CHAPTER 7: RNA BASED THERAPEUTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast, by region
7.2. North America
7.2.1. Key trends and growth opportunities
7.2.2. Market size and forecast, by type
7.2.3. Market size and forecast, by application
7.2.4. Market size and forecast, by end user
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.2. U.S. market size and forecast, by type
7.2.6. Market size and forecast, by application
7.2.6.1. U.S. market size and forecast, by end user
7.2.6.2. Canada
7.2.6.3. Canada market size and forecast, by type
7.2.6.4. Canada market size and forecast, by application
7.2.6.5. Canada market size and forecast, by end user
7.2.6.6. Mexico
7.2.6.7. Mexico market size and forecast, by type
7.2.6.8. Mexico market size and forecast, by application
7.2.6.9. Mexico market size and forecast, by end user
7.3. Europe
7.3.1. Key trends and growth opportunities
7.3.2. Market size and forecast, by type
7.3.3. Market size and forecast, by application
7.3.4. Market size and forecast, by end user
7.3.5. Market size and forecast, by country
7.3.5.1. Germany.
7.3.5.2. Germany market size and forecast, by type
7.3.5.3. Germany market size and forecast, by application
7.3.5.4. Germany market size and forecast, by end user
7.3.5.5. France
7.3.5.6. France market size and forecast, by type
7.3.5.7. France market size and forecast, by application
7.3.5.8. France market size and forecast, by end user
7.3.5.9. UK
7.3.5.10. UK market size and forecast, by type
7.3.5.11. UK market size and forecast, by application
7.3.5.12. UK market size and forecast, by end user
7.3.5.13. Italy
7.3.5.14. Italy market size and forecast, by type
7.3.5.15. Italy market size and forecast, by application
7.3.5.16. Italy market size and forecast, by end user
7.3.5.17. Spain
7.3.5.18. Spain market size and forecast, by type
7.3.5.19. Spain market size and forecast, by application
7.3.5.20. Spain market size and forecast, by end user
7.3.5.21. Rest of Europe
7.3.5.22. Rest of Europe market size and forecast, by type
7.3.5.23. Rest of Europe market size and forecast, by application
7.3.5.24. Rest of Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key trends and growth opportunities
7.4.2. Market size and forecast, by type
7.4.3. Market size and forecast, by application
7.4.4. Market size and forecast, by end user
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.2. Japan market size and forecast, by type
7.4.5.3. Japan market size and forecast, by application
7.4.5.4. Japan market size and forecast, by end user
7.4.5.5. China
7.4.5.6. China market size and forecast, by type
7.4.5.7. China market size and forecast, by application
7.4.5.8. China market size and forecast, by end user
7.4.5.9. India
7.4.5.10. India market size and forecast, by type
7.4.5.11. India market size and forecast, by application
7.4.5.12. India market size and forecast, by end user
7.4.5.13. Australia
7.4.5.14. Australia market size and forecast, by type
7.4.5.15. Australia market size and forecast, by application
7.4.5.16. Australia market size and forecast, by end user
7.4.5.17. South Korea
7.4.5.18. South Korea market size and forecast, by type
7.4.5.19. South Korea market size and forecast, by application
7.4.5.20. South Korea market size and forecast, by end user
7.4.5.21. Rest of Asia-Pacific
7.4.5.22. Rest of Asia-Pacific market size and forecast, by type
7.4.5.23. Rest of Asia-Pacific market size and forecast, by application
7.4.5.24. Rest of Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by type
7.5.3. Market size and forecast, by application
7.5.4. Market size and forecast, by end user
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.2. Brazil market size and forecast, by type
7.5.5.3. Brazil market size and forecast, by application
7.5.5.4. Brazil market size and forecast, by end user
7.5.5.5. Saudi Arabia
7.5.5.6. Saudi Arabia market size and forecast, by type
7.5.5.7. Saudi Arabia market size and forecast, by application
7.5.5.8. Saudi Arabia market size and forecast, by end user
7.5.5.9. South Africa
7.5.5.10. South Africa market size and forecast, by type
7.5.5.11. South Africa market size and forecast, by application
7.5.5.12. South Africa market size and forecast, by end user
7.5.5.13. Rest of LAMEA
7.5.5.14. Rest of LAMEA market size and forecast, by type
7.5.5.15. Rest of LAMEA market size and forecast, by application
7.5.5.16. Rest of LAMEA market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. Alnylam Pharmaceuticals Inc
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. Arbutus Biopharma Corporation
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. Arrowhead Pharmaceuticals
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. Benitec Biopharma Inc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. Biogen
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Gradalis, Inc.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segment
8.6.4. Product portfolio
8.7. Genzyme (Sanofi), Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. Ionis Pharmaceuticals, Inc.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Sarepta Therapeutics
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. Silence Therapeutics plc
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
List of Tables
TABLE 01. RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030($MILLION)
TABLE 02. RNA BASED THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI), BY REGION, 2020-2030($MILLION)
TABLE 03. RNA BASED THERAPEUTICS MARKET FOR RNA ANTISENSE, BY REGION, 2020-2030($MILLION)
TABLE 04. RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030($MILLION)
TABLE 05. RNA BASED THERAPEUTICS MARKET FOR GENETIC DISORDERS, BY REGION, 2020-2030 ($MILLION)
TABLE 06. RNA BASED THERAPEUTICS MARKET FOR AUTO IMMUNE DISORDERS, BY REGION, 2020-2030($MILLION)
TABLE 07. RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030($MILLION)
TABLE 08. RNA BASED THERAPEUTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2020-2030($MILLION)
TABLE 09. RNA BASED THERAPEUTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020-2030 ($MILLION)
TABLE 10. RNA BASED THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 11. NORTH AMERICA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 12. NORTH AMERICA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 13. NORTH AMERICA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 14. NORTH AMERICA RNA BASED THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 15. U.S. RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 16. U.S. RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 17. U.S. RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 18. CANADA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 19. CANADA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 20. CANADA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 21. MEXICO RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 22. MEXICO RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 23. MEXICO RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 24. EUROPE RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 25. EUROPE RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 26. EUROPE RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 27. EUROPE RNA BASED THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 28. GERMANY RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 29. GERMANY RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 30. GERMANY RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 31. FRANCE RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 32. FRANCE RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 33. FRANCE RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 34. UK RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 35. UK RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 36. UK RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 37. ITALY RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 38. ITALY RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 39. ITALY RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 40. SPAIN RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 41. SPAIN RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 42. SPAIN RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 43. REST OF EUROPE RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 44. REST OF EUROPE RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 45. REST OF EUROPE RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 46. ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 47. ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 48. ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 49. ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 50. JAPAN RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 51. JAPAN RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 52. JAPAN RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 53. CHINA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 54. CHINA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 55. CHINA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 56. INDIA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 57. INDIA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 58. INDIA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 59. AUSTRALIA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 60. AUSTRALIA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 61. AUSTRALIA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 62. SOUTH KOREA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 63. SOUTH KOREA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 64. SOUTH KOREA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 65. REST OF ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 66. REST OF ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 68. LAMEA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 69. LAMEA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 70. LAMEA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 71. LAMEA RNA BASED THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 72. BRAZIL RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 73. BRAZIL RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 74. BRAZIL RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 75. SAUDI ARABIA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 76. SAUDI ARABIA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 77. SAUDI ARABIA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 78. SOUTH AFRICA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 79. SOUTH AFRICA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 80. SOUTH AFRICA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 81. REST OF LAMEA RNA BASED THERAPEUTICS MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 82. REST OF LAMEA RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 83. REST OF LAMEA RNA BASED THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 84. ALNYLAM: COMPANY SNAPSHOT
TABLE 85. ALNYLAM: OPERATING SEGMENTS
TABLE 86. ALNYLAM: PRODUCT PORTFOLIO
TABLE 87. ALNYLAM.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 88. ARBUTUS: COMPANY SNAPSHOT
TABLE 89. ARBUTUS SEGMENTS
TABLE 90. ARBUTUS: PRODUCT PORTFOLIO
TABLE 91. ARROWHEAD: COMPANY SNAPSHOT
TABLE 92. ARROWHEAD: OPERATING SEGMENT
TABLE 93. ARROWHEAD: PRODUCT PORTFOLIO
TABLE 94. BENITEC: COMPANY SNAPSHOT
TABLE 95. BENITEC: OPERATING SEGMENTS
TABLE 96. BENITEC: PRODUCT PORTFOLIO
TABLE 97. BIOGEN: COMPANY SNAPSHOT
TABLE 98. BIOGEN: OPERATING SEGMENTS
TABLE 99. BIOGEN: PRODUCT PORTFOLIO
TABLE 100. GRADALIS: COMPANY SNAPSHOT
TABLE 101. GRADALIS: OPERATING SEGMENT
TABLE 102. GRADALIS: PRODUCT PORTFOLIO
TABLE 103. GENZYME: COMPANY SNAPSHOT
TABLE 104. GENZYME: OPERATING SEGMENTS
TABLE 105. SANOFI: PRODUCT PORTFOLIO
TABLE 106. SANOFI.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 107. IONIS: COMPANY SNAPSHOT
TABLE 108. IONIS: OPERATING SEGMENTS
TABLE 109. IONIS: PRODUCT PORTFOLIO
TABLE 110. SAREPTA: COMPANY SNAPSHOT
TABLE 111. SAREPTA: OPERATING SEGMENT
TABLE 112. SAREPTA: PRODUCT PORTFOLIO
TABLE 113. SAREPTA.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114. SILENCE: COMPANY SNAPSHOT
TABLE 115. SILENCE OPERATING SEGMENTS
TABLE 116. SILENCE: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. RNA BASED THERAPEUTICS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES: BY DEVELOPMENT, 2018-2021 (%)
FIGURE 04. TOP WINNING STRATEGIES: BY DEVELOPMENT, 2018-2021 (%)
FIGURE 05. TOP INVESTMENT POCKETS WINNING STRATEGIES: BY COMPANY, 2018-2021 (%)
FIGURE 06. TOP PLAYER POSITIONING, 2020
FIGURE 07. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08. HIGH BARGAINING POWER OF BUYERS
FIGURE 09. HIGH THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE THREAT OF SUBSTITUTES
FIGURE 11. MODERATR INTENSITY OF COMPETITIVE RIVALRY
FIGURE 12. IMPACT ANALYSES, RNA BASED THERAPEUTICS MARKET
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) BY COUNTRY, 2020 & 2030 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR RNA ANTISENSE BY COUNTRY, 2020 & 2030 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR GENETIC DISORDERS BY COUNTRY, 2020 & 2030 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR AUTO IMMUNE DISORDERS BY COUNTRY, 2020 & 2030 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR RESEARCH INSTITUTES BY COUNTRY, 2020 & 2030 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF RNA BASED THERAPEUTICS MARKET FOR HOSPITALS & CLINICS BY COUNTRY, 2020 & 2030 (%)
FIGURE 19. ALNYLAM: NET SALES, 2018-2020 ($MILLION)
FIGURE 20. ALNYLAM: REVENUE SHARE BY REGION, 2020(%)
FIGURE 21. ARBUTUS: NET SALES, 2018-2020 ($MILLION)
FIGURE 22. ARROWHEAD: NET SALES, 2018-2020 ($MILLION)
FIGURE 23. BENITEC: NET SALES, 2018-2020 ($MILLION)
FIGURE 24. BIOGEN: NET SALES, 2018-2020 ($MILLION)
FIGURE 25. BIOGEN: REVENUE SHARE BY REGION, 2020(%)
FIGURE 26. GENZYME: NET SALES, 2018-2020 ($MILLION)
FIGURE 27. GENZYME: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 28. GENZYME: REVENUE SHARE BY REGION, 2020(%)
FIGURE 29. IONIS: NET SALES, 2018-2020 ($MILLION)
FIGURE 30. IONIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31. SAREPTA: NET SALES, 2018-2020 ($MILLION)

Companies Mentioned

  • Alnylam Pharmaceuticals Inc.
  • Silence Therapeutics plc
  • Arbutus Biopharma Corporation
  • Genzyme (Sanofi)
  • Ionis Pharmaceuticals
  • Sarepta Therapeutics
  • Benitec Biopharma Inc.
  • Arrowhead Pharmaceuticals
  • Biogen Inc
  • Gradalis, Inc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...